Juniper pharmaceuticals inc (JNP)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Class of Stock
Class of Stock
Series C Preferred Stock [Member]
Operating activities:
Net loss

-

-

-

-

-

-

-

-

-21,869

Net income (loss)

-2,060

5,951

-1,496

4,656

4,741

9,917

20,527

-21,830

-

Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization

2,253

1,899

1,911

1,992

919

642

166

3,161

5,737

Amortization of beneficial conversion features

-

-

-

-

-

-

-

-918

-1,658

Amortization of warrants

-

-

-

-

-

-

-

673

1,231

Gain on sale of STRIANT

-

-

-

-

-

-

2,533

0

0

Change in fair value of common stock warrants

-

-

-

-379

-794

-6,995

2,164

-

-

Provision for sales returns

-

-

-

-

26

625

-

-

-

Stock-based compensation expense

1,469

1,201

1,750

607

475

-

-

-

-

Gain on sale of short-term investments

-

-

-

-

17

-

-

-

-

Write-off of inventories

-

-

-

-

-

970

58

41

81

Recognition of deferred provision for sales returns

-

-

-

-

-

-

-17,113

-

-

Change in value of redeemable warrants

-

-

-

-

-

-

-

7,961

0

Change in fair value of stock warrants

-

-

-

-

-

-

-

5,229

0

Recognition of deferred income

-

-

-

-

-

-

-

17,366

52

Loss on extinguishment of debt

-

-

-

-

-

-

-

-5,156

0

(Credit) provision for doubtful accounts

-

-

-

-

-

-

-

59

0

Provision for sales returns

-

-

-

-

-

-

358

1,781

1,226

Write-off of accounts receivable

-

-

-

-

-

-

-7

0

-

Write-off of accounts receivable

-

-

-

-

-

-

-

-

0

Stock-based compensation expense

-

-

-

-

-

668

814

2,800

1,749

Deferred tax liability

-

-

-

542

57

-

-

-

-

Non-cash interest expense on financing agreements

-

-

-

-

-

-

-

1,137

2,085

Write-down of impaired assets

-

-

-

-

-

890

-

0

-

Loss on disposal of fixed assets

-

-

-

-

-37

-8

-3

0

0

Changes in operating assets and liabilities:
Accounts receivable

-2,178

-192

2,499

-1,705

2,347

-1,776

902

-62

700

Due from related party

-

-

-

-900

-1,295

68

-568

-

-

Inventories

704

1,998

424

619

-46

-39

1,396

94

237

Prepaid expenses and other current assets

1,849

-64

-259

331

-1,439

616

275

-599

-5

Other non-current assets

-17

-18

89

5

50

-425

-19

0

-9

Accounts payable

183

1,585

-925

91

315

-2,456

-2,095

1,731

1,576

Accrued expenses

225

1,214

1,591

-896

-510

-218

-1,838

-1,870

-1,632

Deferred revenue

455

1,033

-1,038

-1,334

1,493

-13

125

125

74

Other long-term liabilities

-40

27

69

-

-

-

-

-

-

Net cash used in operating activities

2,127

11,186

-891

6,929

7,073

4,344

-

-

-

Net cash provided by operating activities

-

-

-

-

-

-

-1,339

-9,723

-9,055

Investing activities:
Purchases of property and equipment

2,840

3,564

1,708

2,048

522

986

1,307

42

49

Redemption of series C convertible preferred stock

-

-

-

-

-

50

-

0

-

Proceeds from sale of assets

-

-

-

-

-

-

-

35,240

0

Proceeds from the sale of STRIANT

-

-

-

-

-

-

3,100

0

0

Net cash used in investing activities

-

-

-

-

-

-

-13,309

35,197

-49

Financing activities:
Additions to short-term investments

-

-

-

-

-

235

15,101

0

0

Cash paid for acquisition, net of cash received

-

-

-

-

14,516

-

-

-

-

Proceeds from the sale of short-term investments

-

-

-

-

15,353

-

-

-

-

Net cash used in investing activities

-2,840

-3,564

-1,708

-2,048

315

-1,221

-

-

-

Proceeds from exercise of stock options

-

-

82

33

11

0

2,641

79

0

Proceeds from loan facility

954

-

-

-

-

-

-

-

-

Proceeds from equipment loans

1,501

-

-

-

-

-

-

-

-

Principal payments on debt

1,402

226

238

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

653

0

0

Net proceeds from issuance of common stock and warrants

-

-

-

-

-

-

-

11,643

11,456

Proceeds from financing agreements - Actavis Note

-

-

-

-

-

-

-

15,000

0

Principal payments on notes payable

-

-

-

245

72

-

-

25,999

0

Repurchase of company stock

-

-

-

-

-

-

-

3,059

0

Payment pursuant to financing agreements

-

-

-

-

-

-

-

16,155

0

Payments for the purchase of treasury stock

-

-

22

8,509

-

-

125

62

91

Dividends paid

14

28

28

28

28

29

30

30

32

Net cash provided by financing activities

1,039

-254

-206

-8,749

-89

-79

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

3,139

-18,585

11,332

Effect of exchange rate changes on cash and cash equivalents

126

-275

-56

-85

212

46

-7

-15

33

Net (decrease) increase in cash and cash equivalents

452

7,093

-2,861

-3,953

7,511

3,090

-11,516

6,873

2,260

Supplemental cash flow information
Cash paid for interest

115

85

101

120

25

-

-

1,608

3,200

Cash paid for income taxes

76

-

2

3

3

-

220

77

52

Supplemental noncash information
Purchases of equipment through accounts payable and accrued expenses

320

460

95

-

-

-

-

-

-

Reclassification of redeemable warrant liability to capital in excess of par value

-

-

-

-

-

-

-

0

-

Retirement of warrant liability

-

-

-

-

-

-

-

0

-

Issuance of Warrants for Option to Extend Pharmabio Debt

-

-

-

-

-

-

-

-

719

Forgiveness of Actavis Note

-

-

-

-

-

-

-

15,000

0

Common stock issued in connection with the acquisition of Juniper Pharma Services

-

-

-

-

7,295

-

-

7,738

0

Conversion of stock

-

-

-

-

-

-

-

-

175

Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants

-

-

-

-

-

-

-

5,509

-

Issuance of Warrants for Debt Retirement

-

-

-

-

-

-

-

-

0